Here we present the development of a modular platform for safe and effective systemic administration of STING agonists based on the concept of “albumin-hitchhiking.”26 Albumin is a promising drug carrier based on its long circulation half-life and proclivity to accumulate at tumor sites via both passive and active transport mechanisms.27–29 Albumin and albumin-binding chaperones have been widely employed to improve the delivery of chemotherapeutics, exemplified by albumin-bound paclitaxel (Abraxane®)30, as well as protein31, peptide32, and nucleic acid therapeutics30. Here, STING1 is linked to neoplasm.